New Unacylated Ghrelin Analog for Diabetes Treatment
AZP-531, the first unacylated ghrelin analog., is the result of a UAG development programme started in 2007: This 8-amino acid peptide is stable and its pharmacokinetic properties make it suitable for pharmaceutical development. AZP-531 will be the first unacylated ghrelin analog to enter regulatory development, company speakers belive.
“The mechanism of action of AZP-531 may lead to improved glycemia control in type II diabetes and also to positive effects on other cardiovascular risk factors, such as obesity, dyslipidemia and vascular complications,” explained Professor AJ van der Lely, head of the clinical endocrinology department at the Erasmus Medical Center in Rotterdam (Netherlands) and scientific advisor at Alize Pharma. “In addition, it could be used to target clinical conditions where acylated ghrelin levels are abnormally high, such as the Prader Willi syndrome, thus opening up a new treatment option for these patients.”
Portfolio of 34 Pharmaceutical Patents
Currently Alize Pharma owns a portfolio of five families of patents comprising a total of 34 patents and patent applications for the protection of UAG, its analogs, including AZP-531, and their applications. Professor AJ van der Lely and his team will present new clinical data on the effects of unacylated ghrelin in diabetic patients at the upcoming annual meeting of the Endocrine Society (ENDO 2012) that will be held in Houston from June 23 to 26, 2012.